Japanese Government Funds Arcturus Therapeutics with $115M for mRNA Vaccine Production Expansion

San Diego’s RNA biotech firm, Arcturus Therapeutics, has received a $115 million grant from the Japanese government for its manufacturing operations, Arcalis Co., Ltd. The joint venture between Arcturus and Tokyo-based company Axcelead will build a Minamisoma City factory to produce materials for mRNA-based vaccines and medicines. The anticipated completion of the site’s expansion is in 2026. Arcturus is developing several vaccines, including those for COVID-19 and flu, in addition to treatments for a rare condition called ornithine transcarbamylase deficiency and cystic fibrosis.

To read more, click here.